Contract facts
UnrestrictedNo full NAICS 325412 intel page yet. Browse NAICS intelligence
Nuclear Medicine Imaging Products for Myocardial Infarct Imaging, Diagnostic Imaging of Gall Bladder Disorders, and Bre… is a federal Unrestricted award for Defense Health Agency held by Sun Pharmaceutical Industries, Inc. Estimated value $1M ($967K obligated). Current period of performance ends Mar 10, 2027. Last award drew 3 bidders. Place of performance: BETHESDA MD.
Nuclear medicine imaging products for myocardial infarct imaging, diagnostic imaging of gall bladder disorders, and breast cancer nodule imaging medicine. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Mar 10, 2027 (144 days remaining). Agencies typically plan 12–18 months ahead — at 4.7 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on HT001422P0039? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordSun Pharmaceutical Industries, Inc — $724K obligated across 7 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT001422P0039?
HT001422P0039 (Nuclear medicine imaging products for myocardial) is a Defense Health Agency award with a potential value of $1M, currently held by Sun Pharmaceutical Industries, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT0014-22-P-0039?
HT0014-22-P-0039 is the dashed form of PIID HT001422P0039 (Nuclear medicine imaging products for myocardial), held by Sun Pharmaceutical Industries, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT001422P0039?
Defense Health Agency awarded HT001422P0039 to Sun Pharmaceutical Industries, Inc (potential $1M).
Who is the incumbent on HT001422P0039?
Sun Pharmaceutical Industries, Inc is the incumbent with $724K across 7 related awards in SCOUT’s public footprint. The current period of performance ends Mar 10, 2027.
When does Sun Pharmaceutical Industries, Inc’s HT001422P0039 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 10, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HT001422P0039? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.